Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
暂无分享,去创建一个
H. Verheul | H. Pinedo | R. Hanemaaijer | H. Broxterman | Y. van Hensbergen | K. Hoekman | N. van Lent | A. S. Jorna
[1] E. Favaloro,et al. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. , 1993, Clinica chimica acta; international journal of clinical chemistry.
[2] P. Koolwijk,et al. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. , 1998, Matrix biology : journal of the International Society for Matrix Biology.
[3] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[4] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[5] J. Verheijen,et al. Determination of Gelatinase‐A (MMP‐2) Activity Using a Novel Immunocapture Assay , 1999, Annals of the New York Academy of Sciences.
[6] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[7] M. Dewhirst,et al. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. , 1999, Cancer research.
[8] J. Richardson,et al. Diagnosis and management of malignant pleural effusions. , 1995, American journal of surgery.
[9] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[10] S. Zucker,et al. Human pleural effusions are rich in matrix metalloproteinases. , 1992, Chest.
[11] R. Light,et al. Vascular endothelial growth factor in pleural fluid. , 1999, Chest.
[12] H. Verheul,et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Feldman,et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] T. Tsuruo,et al. Role of aminopeptidase N (CD13) in tumor‐cell invasion and extracellular matrix degradation , 1993, International journal of cancer.
[15] A. Harris,et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] V. V. van Hinsbergh,et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity , 1996, The Journal of cell biology.
[17] W. Arap,et al. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. , 2001, Blood.
[18] T. Tsuruo,et al. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13 , 1995, Clinical & Experimental Metastasis.
[19] E. Favaloro,et al. CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. , 1993, Experimental hematology.
[20] Gordon B. Mills,et al. Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites , 1999, Annals of Surgical Oncology.
[21] A. Harris,et al. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. , 1994, Journal of clinical pathology.
[22] A. Harris,et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] D. Marmé,et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.
[24] D. Thickett,et al. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions , 1999, Thorax.
[25] R K Jain,et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.
[26] T. Salo,et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation , 2001, British Journal of Cancer.
[27] F. Reichenberger,et al. MMP and TIMP expression pattern in pleural effusions of different origins. , 1997, American journal of respiratory and critical care medicine.
[28] D. Sane,et al. Vascular Origin of a Soluble Truncated Form of the Hepatocyte Growth Factor Receptor (c-met) , 2002, Circulation research.
[29] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[30] J. Riordan,et al. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. , 1991, Biochemistry.
[31] V. Gerkis,et al. Variable O-glycosylation of CD13 (aminopeptidase N). , 1991, The Journal of biological chemistry.
[32] J. Newcombe,et al. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. , 2001, Brain : a journal of neurology.
[33] S. Sahn. Pleural diseases related to metastatic malignancies. , 1997, The European respiratory journal.
[34] D. Hicklin,et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] N. Sakuragi,et al. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. , 2000, Gynecologic oncology.
[36] V. Bertone,et al. Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. , 1997, Anticancer research.
[37] E. Favaloro. CD‐13 (‘gp150’; aminopeptidase‐N): Co‐expression on endothelial and haemopoietic cells with conservation of functional activity , 1991, Immunology and cell biology.
[38] H. Höfler,et al. Ovarian Prognostic Significance of Urokinase (upa) and Its Inhibitor Pai-1 for Survival in Advanced Ovarian Carcinoma Stage Figo Iiic , 2022 .
[39] R. Ashmun,et al. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. , 1989, The Journal of clinical investigation.
[40] S. Nicosia,et al. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.